Cerebrospinal Fluid β-Amyloid and Tau Proteins for the Diagnosis of Alzheimer Disease

Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment

“…In conclusion, the results of this ongoing study suggest that the CSF biochemical marker profile typical for ADelevated tau and decreased A␤42 levels-may often be present at a predementia stage of the disease. Therefore, our study provides preliminary evidence that CSF markers may have high predictive power 15 to identify subjects with MCI who have the greatest risk of progressing to clinically diagnosable AD. Shifting the diagnostic threshold to the predementia stage is of paramount importance with respect to future disease-modifying treatment strategies.…”

Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment

“…In conclusion, the results of this ongoing study suggest that the CSF biochemical marker profile typical for ADelevated tau and decreased A␤42 levels-may often be present at a predementia stage of the disease. Therefore, our study provides preliminary evidence that CSF markers may have high predictive power 15 to identify subjects with MCI who have the greatest risk of progressing to clinically diagnosable AD. Shifting the diagnostic threshold to the predementia stage is of paramount importance with respect to future disease-modifying treatment strategies.…”

Plasma haptoglobin and immunoglobulins as diagnostic indicators of deoxynivalenol intoxication

“…Many candidate biomarkers have been found by the SELDI-TOF/MS technique such as amyloid-β peptide for Alzheimer's disease [14,28], α-defensin 1, 2 and 3 for immunodeficiency and so on [38]. …”

CSF Biomarkers for Alzheimer’s Disease: Levels of β-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival

“…A clinically useful diagnostic marker should have a sensitivity exceeding 80% and a specifi city above 80% according to the statement of the Consensus Group for Biomarkers [37] . The combination of the three CSF biomarkers enhances the precision of the AD diagnosis [21] .…”

“…The need for increased diagnostic precision is obvious, since the accuracy of the clinical diagnosis of AD has been reported to be not more than 65-90% in autopsy-verifi ed AD cases [38][39][40] . To investigate the CSF biomarkers in studies involving autopsy confi rmation would be the fi nal step toward a comprehensive understanding of the diagnostic usefulness of these CSF biomarkers [21] . However, practical and ethical diffi culties often stand in the way of obtaining postmortem confi rmation.…”

Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment

“…In conclusion, the results of this ongoing study suggest that the CSF biochemical marker profile typical for ADelevated tau and decreased A␤42 levels-may often be present at a predementia stage of the disease. Therefore, our study provides preliminary evidence that CSF markers may have high predictive power 15 to identify subjects with MCI who have the greatest risk of progressing to clinically diagnosable AD. Shifting the diagnostic threshold to the predementia stage is of paramount importance with respect to future disease-modifying treatment strategies.…”

Plasma haptoglobin and immunoglobulins as diagnostic indicators of deoxynivalenol intoxication

“…Many candidate biomarkers have been found by the SELDI-TOF/MS technique such as amyloid-β peptide for Alzheimer's disease [14,28], α-defensin 1, 2 and 3 for immunodeficiency and so on [38]. …”

CSF Biomarkers for Alzheimer’s Disease: Levels of β-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival

“…A clinically useful diagnostic marker should have a sensitivity exceeding 80% and a specifi city above 80% according to the statement of the Consensus Group for Biomarkers [37] . The combination of the three CSF biomarkers enhances the precision of the AD diagnosis [21] .…”

“…The need for increased diagnostic precision is obvious, since the accuracy of the clinical diagnosis of AD has been reported to be not more than 65-90% in autopsy-verifi ed AD cases [38][39][40] . To investigate the CSF biomarkers in studies involving autopsy confi rmation would be the fi nal step toward a comprehensive understanding of the diagnostic usefulness of these CSF biomarkers [21] . However, practical and ethical diffi culties often stand in the way of obtaining postmortem confi rmation.…”

Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive Impairment

“…In conclusion, the results of this ongoing study suggest that the CSF biochemical marker profile typical for ADelevated tau and decreased A␤42 levels-may often be present at a predementia stage of the disease. Therefore, our study provides preliminary evidence that CSF markers may have high predictive power 15 to identify subjects with MCI who have the greatest risk of progressing to clinically diagnosable AD. Shifting the diagnostic threshold to the predementia stage is of paramount importance with respect to future disease-modifying treatment strategies.…”

Plasma haptoglobin and immunoglobulins as diagnostic indicators of deoxynivalenol intoxication

“…Many candidate biomarkers have been found by the SELDI-TOF/MS technique such as amyloid-β peptide for Alzheimer's disease [14,28], α-defensin 1, 2 and 3 for immunodeficiency and so on [38]. …”

CSF Biomarkers for Alzheimer’s Disease: Levels of β-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival

“…A clinically useful diagnostic marker should have a sensitivity exceeding 80% and a specifi city above 80% according to the statement of the Consensus Group for Biomarkers [37] . The combination of the three CSF biomarkers enhances the precision of the AD diagnosis [21] .…”

“…The need for increased diagnostic precision is obvious, since the accuracy of the clinical diagnosis of AD has been reported to be not more than 65-90% in autopsy-verifi ed AD cases [38][39][40] . To investigate the CSF biomarkers in studies involving autopsy confi rmation would be the fi nal step toward a comprehensive understanding of the diagnostic usefulness of these CSF biomarkers [21] . However, practical and ethical diffi culties often stand in the way of obtaining postmortem confi rmation.…”